A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Transaction increases annual revenue to $44M and is expected to accelerate time to breakeven, following recently announced acquisition of Innovus Pharmaceuticals Total upfront consideration equals 1.4x LTM revenue plus assumption of debt Triples size of Rx product...
Armistice Capital and Altium Capital jointly participated in financing ENGLEWOOD, CO / October 14, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical...
Co-Promotion Expands Physician Promotion of Aytu's Prescription Sleep Aid with Dedicated Specialty Sales Force, into Psychiatry Market, Which Accounted for Over 2.7 Million Zolpidem Tartrate Prescriptions for The Twelve Months Ending August 2019 Aytu's third announced...
Results Do Not Include September 2019 Definitive Agreement to Acquire Innovus Pharmaceuticals: Combined LTM revenues of over $31M, Diversifies product line by 10x to over 30 products ENGLEWOOD, CO / September 26, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty...
During the 12-month period ending June 2019, the U.S. prescription TRT market registered 6.9 million prescriptions, generating approximately $1.7 billion in revenue ENGLEWOOD, CO / September 24, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical...
ENGLEWOOD, CO / September 19, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that the company will present its operational results for the...
ENGLEWOOD, CO / September 17, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that Josh Disbrow, Chairman and Chief Executive Officer, and...
Acquisition Gives Aytu Timely Entry into Growing Consumer Healthcare Market with a Portfolio of Over 30 Products that Generated $24M of Revenue During Past Four Quarters Combination Will Create Specialty Rx and Consumer Pharma Company with Revenue of $31M New...
Androcryos, South Africa's Largest Sperm Bank, First Laboratory in Africa to Offer MiOXSYS Test ENGLEWOOD, CO / September 10, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products...
Co-promotion nearly doubles Tuzistra XR sales force Poly's geographic footprint covers approximately 750,000 antitussive prescriptions annually accounting for approximately $128 million in annual revenue ENGLEWOOD, CO / September 4, 2019 / Aytu BioScience, Inc....